In this episode, FirstWord Pharma PLUS editors Virginia Li, Michael Flanagan and Simon King share their post-ESMO thoughts on exciting new clinical data in HER2-positive breast cancer, further emergence of the KRAS inhibitors into colorectal cancer and multiple developments in the field of gastric cancer.